Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
Not available.
Saved in:
Main Authors: | Pierre Peterlin, Maxime Jullien |
---|---|
Format: | Article |
Language: | English |
Published: |
Ferrata Storti Foundation
2025-01-01
|
Series: | Haematologica |
Online Access: | https://haematologica.org/article/view/11927 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
by: Qian Yan, et al.
Published: (2025-01-01) -
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
by: Thomas Cluzeau, et al.
Published: (2025-02-01) -
Molecular Targets for the Treatment of Juvenile Myelomonocytic Leukemia
by: Xiaoling Liu, et al.
Published: (2012-01-01) -
Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease
by: Feng Li, et al.
Published: (2018-01-01) -
Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
by: Romane Joudinaud, et al.
Published: (2025-01-01)